Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Gwyn Bebb

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Current Oncology (Toronto, Ont.)|August 26, 2021
Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in CanadaDylan E O'Sullivan, Winson Y Cheung, Iqra A Syed, et al.
British Journal of Cancer|September 5, 2019
Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cellsNicholas R Jette, Suraj Radhamani, Greydon Arthur, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 31, 2011
CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancerShannon Otsuka, Alexander C Klimowicz, Karen Kopciuk, et al.
Cancers|November 6, 2019
The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint InhibitorsDaniel E Meyers, Igor Stukalin, Isabelle A Vallerand, et al.
EMBO Molecular Medicine|March 15, 2012
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53Chris T Williamson, Eiji Kubota, Jeffrey D Hamill, et al.
Oncotarget|April 19, 2017
Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLCLars F Petersen, Alexander C Klimowicz, Shannon Otsuka, et al.
Current Oncology (Toronto, Ont.)|October 22, 2021
Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy DatabaseHeidi A I Grosjean, Samantha Dolter, Daniel E Meyers, et al.
Current Oncology (Toronto, Ont.)|January 20, 2021
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in AdultsD Gwyn Bebb, Shantanu Banerji, Normand Blais, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Current Oncology (Toronto, Ont.)|August 26, 2021
Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in CanadaDylan E O'Sullivan, Winson Y Cheung, Iqra A Syed, et al.
British Journal of Cancer|September 5, 2019
Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cellsNicholas R Jette, Suraj Radhamani, Greydon Arthur, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 31, 2011
CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancerShannon Otsuka, Alexander C Klimowicz, Karen Kopciuk, et al.
Cancers|November 6, 2019
The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint InhibitorsDaniel E Meyers, Igor Stukalin, Isabelle A Vallerand, et al.
EMBO Molecular Medicine|March 15, 2012
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53Chris T Williamson, Eiji Kubota, Jeffrey D Hamill, et al.
Oncotarget|April 19, 2017
Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLCLars F Petersen, Alexander C Klimowicz, Shannon Otsuka, et al.
Current Oncology (Toronto, Ont.)|October 22, 2021
Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy DatabaseHeidi A I Grosjean, Samantha Dolter, Daniel E Meyers, et al.
Current Oncology (Toronto, Ont.)|January 20, 2021
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in AdultsD Gwyn Bebb, Shantanu Banerji, Normand Blais, et al.
Pageof 3